BGLC BioNexus Gene Lab Corp
Price (delayed)
$0.2531
Market cap
$4.55M
P/E Ratio
25.31
Dividend/share
N/A
EPS
$0.01
Enterprise value
$2.73M
Highlights
The EPS has soared by 108% from the previous quarter and by 105% YoY
The net income has soared by 70% YoY and by 57% from the previous quarter
The debt has surged by 77% year-on-year but it has declined by 46% since the previous quarter
The quick ratio has declined by 18% since the previous quarter and by 9% year-on-year
BioNexus Gene Lab's gross profit has decreased by 11% YoY and by 2.2% QoQ
Key stats
What are the main financial stats of BGLC
Market
Valuations
Earnings
Shares outstanding
17.97M
Market cap
$4.55M
Enterprise value
$2.73M
Price to earnings (P/E)
25.31
Price to book (P/B)
0.48
Price to sales (P/S)
0.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
Revenue
$9.26M
Gross profit
$1.25M
Operating income
-$2.27M
Net income
-$941,560
EBIT
-$899,728
EBITDA
-$759,954
Free cash flow
-$2.65M
Per share
Balance sheet
Liquidity
EPS
$0.01
EPS diluted
$0.01
Free cash flow per share
-$0.15
Book value per share
$0.52
Revenue per share
$0.52
TBVPS
$0.61
Total assets
$11M
Total liabilities
$1.61M
Debt
$245,142
Equity
$9.39M
Working capital
$5.62M
Debt to equity
0.03
Current ratio
4.98
Quick ratio
3.98
Net debt/EBITDA
2.39
Margins
Efficiency
Dividend
EBITDA margin
-8.2%
Gross margin
13.5%
Net margin
-10.2%
Operating margin
-24.5%
Return on assets
-8.4%
Return on equity
-9.9%
Return on invested capital
-11.9%
Return on capital employed
-9.4%
Return on sales
-9.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BGLC stock price
How has the BioNexus Gene Lab stock price performed over time
Intraday
-2.65%
1 week
-20.91%
1 month
-22.72%
1 year
-58.17%
YTD
-9.51%
QTD
7.06%
Financial performance
How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$9.26M
Gross profit
$1.25M
Operating income
-$2.27M
Net income
-$941,560
Gross margin
13.5%
Net margin
-10.2%
The net income has soared by 70% YoY and by 57% from the previous quarter
The net margin has surged by 66% year-on-year and by 58% since the previous quarter
The operating income has increased by 35% year-on-year and by 29% since the previous quarter
BioNexus Gene Lab's operating margin has increased by 30% QoQ and by 28% YoY
Growth
What is BioNexus Gene Lab's growth rate over time
Valuation
What is BioNexus Gene Lab stock price valuation
P/E
25.31
P/B
0.48
P/S
0.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
The EPS has soared by 108% from the previous quarter and by 105% YoY
The P/B is 50% lower than the last 4 quarters average of 1.0
BioNexus Gene Lab's equity has decreased by 3.1% YoY
BGLC's price to sales (P/S) is 50% less than its last 4 quarters average of 1.0
The revenue has declined by 10% year-on-year
Efficiency
How efficient is BioNexus Gene Lab business performance
The return on equity has surged by 77% year-on-year and by 57% since the previous quarter
The return on invested capital has surged by 77% year-on-year and by 61% since the previous quarter
The ROA has soared by 75% YoY and by 57% QoQ
The ROS has soared by 66% YoY and by 57% from the previous quarter
Dividends
What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BGLC.
Financial health
How did BioNexus Gene Lab financials performed over time
The quick ratio has declined by 18% since the previous quarter and by 9% year-on-year
BioNexus Gene Lab's current ratio has decreased by 11% from the previous quarter
The debt is 97% smaller than the equity
The company's debt to equity has surged by 200% YoY but it fell by 40% QoQ
The debt has surged by 77% year-on-year but it has declined by 46% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.